May, 18 2017 12:36 JST

Source: Eisai

Eisai to Present Abstracts on Oncology Products and Pipeline at 53rd ASCO Annual Meeting

Results of Study of Lenvima (Lenvatinib) in Hepatocellular Carcinoma to Be Presented in Oral Session

TOKYO, May, 18 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that a series of abstracts highlighting new study results for its in-house discovered lenvatinib mesylate (selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode, product name: Lenvima / Kisplyx, "lenvatinib") and eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: Halaven, "eribulin"), as well as H3B-8800, a splicing modulator discovered by Eisai's U.S. research subsidiary H3 Biomedicine Inc., will be presented during the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from June 2 to 6, 2017.

Detailed data regarding the results of a Phase III clinical trial (Study 304) of lenvatinib compared with sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma, which has already achieved its primary endpoint, will be presented orally at the ASCO Annual Meeting. This presentation is scheduled to take place on Sunday, June 4, 8:12 AM local time, in Hall D2.

Major poster presentations will include a highlight of the results of a Phase Ib/II clinical trial (Study 111) of lenvatinib in combination with the anti-PD-1 antibody pembrolizumab for the treatment of patients with endometrial carcinoma, and the results of a Phase I clinical trial of H3B-8800 in patients with advanced myeloid malignancies.

Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.


About Eisai
Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2017 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Wellness Open Living Labs. LLC, Co-Founded by Eisai and Osaka City University Conclude Basic Collaboration Agreement Aimed at Solving Health Problems
July 04 2017 08:15 JST
 
Eisai Listed for 16th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment
June 28 2017 17:41 JST
 
Eisai Temporarily Withdraws New Drug Application for Anticancer Agent Halaven in China
June 27 2017 18:54 JST
 
Eisai Submits Application for Additional Indication of Anticancer Agent Lenvima for Hepatocellular Carcinoma in Japan
June 23 2017 18:34 JST
 
Cardiovascular Outcomes Trial of Anti-Obesity Agent Lorcaserin to Continue Based on Recommendation of Independent Data Monitoring Committee After Completion of Interim Safety Analysis
June 23 2017 10:39 JST
 
Launch of Pain Treatment Lyrica OD Tablet Formulation in Japan
June 08 2017 10:07 JST
 
Eisai to Present Results of Phase III Trial of Lenvima (Lenvatinib) as First-Line Treatment for Unresectable Hepatocellular Carcinoma in Oral Session at 53rd ASCO Annual Meeting
June 05 2017 10:22 JST
 
Eisai to Present Results of Phase Ib/II Study of Anticancer Agent Lenvima (Lenvatinib) in Combination With Anti-PD-1 Antibody Pembrolizumab
June 05 2017 09:22 JST
 
Eisai Commits Funding to the 2nd Phase of Global Health Innovative Technology Fund Activities
June 01 2017 16:47 JST
 
Eisai Enters Into a New Joint Research Agreement With the Broad Institute to Develop an Antimalarial Medicine
May 31 2017 09:55 JST
 
More Press release >>

Latest Press Release


More Latest Release >>